Direct Delivery of Plasmin Using Clot-anchoring Thrombin-responsive Nanoparticles for Targeted Fibrinolytic Therapy

Overview

Journal J Thromb Haemost

Publisher Elsevier

Specialty Hematology

Date 2023 Jan 25

PMID 36696210

Authors

Michael Sun

M Hao Hao Pontius

Stephanie Yang

Tejal Pendekanti

Shruti Raghunathan

Jordan A Shavit

Anirban Sen Gupta

Affiliations

Soon will be listed here.

Abstract

Background: Fibrin-rich clot formation in thrombo-occlusive pathologies is currently treated by systemic administration of plasminogen activators (e.g. tPA), to convert fibrin-associated plasminogen to plasmin for fibrinolytic action. However, this conversion is not restricted to clot site only but also occurs on circulating plasminogen, causing systemic fibrinogenolysis and bleeding risks. To address this, past research has explored tPA delivery using clot-targeted nanoparticles.

Objectives: We designed a nanomedicine system that can (1) target clots via binding to activated platelets and fibrin, (2) package plasmin instead of tPA as a direct fibrinolytic agent, and (3) release this plasmin triggered by thrombin for clot-localized action.

Methods: Clot-targeted thrombin-cleavable nanoparticles (CTNPs) were manufactured using self-assembly of peptide-lipid conjugates. Plasmin loading and its thrombin-triggered release from CTNPs were characterized by UV-visible spectroscopy. CTNP-targeting to clots under flow was studied using microfluidics. Fibrinolytic effect of CTNP-delivered plasmin was studied in vitro using BioFlux imaging and D-dimer analysis and in vivo in a zebrafish thrombosis model.

Results: Plasmin-loaded CTNPs significantly bound to clots under shear flow and showed thrombin-triggered enhanced release of plasmin. BioFlux studies confirmed that thrombin-triggered plasmin released from CTNPs rendered fibrinolysis similar to free plasmin, further corroborated by D-dimer analysis. In the zebrafish model, CTNP-delivered plasmin accelerated time-to-recanalization, or completely prevented occlusion when infused before thrombus formation.

Conclusion: Considering that the very short circulation half-life (<1 second) of plasmin prevents its systemic use but also makes it safer without off-target drug effects, clot-targeted delivery of plasmin using CTNPs can enable safer and more efficacious fibrinolytic therapy.

Citing Articles

Injury-on-a-chip for modelling microvascular trauma-induced coagulation.

Deal H, Byrnes E, Pandit S, Sheridan A, Brown A, Daniele M Lab Chip. 2025; 25(3):440-453.

PMID: 39763291 PMC: 11704661. DOI: 10.1039/d4lc00471j.

pH-Responsive Theranostic Colloidosome Drug Carriers Enable Real-Time Imaging of Targeted Thrombolytic Process with Near-Infrared-II for Deep Venous Thrombosis.

Ye Y, Chen Z, Zhang S, Slezak P, Lu F, Xie R Research (Wash D C). 2024; 7:0388.

PMID: 38812529 PMC: 11136571. DOI: 10.34133/research.0388.

Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery.

Ren T, Mi Y, Wei J, Han X, Zhang X, Zhu Q Molecules. 2024; 29(10).

PMID: 38792186 PMC: 11123875. DOI: 10.3390/molecules29102325.

Sono-responsive smart nanoliposomes for precise and rapid hemostasis application.

Zhang Q, Zhu L, Wang K, Chen S, Zhang Y, Song W RSC Adv. 2024; 14(22):15491-15498.

PMID: 38741972 PMC: 11090014. DOI: 10.1039/d3ra08445k.

References

Chernysh I, Nagaswami C, Kosolapova S, Peshkova A, Cuker A, Cines D . The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci Rep. 2020; 10(1):5112. PMC: 7083848. DOI: 10.1038/s41598-020-59526-x. View

Koenig W . Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003; 89(4):601-9. View

Sen Gupta A . Nanomedicine approaches in vascular disease: a review. Nanomedicine. 2011; 7(6):763-79. DOI: 10.1016/j.nano.2011.04.001. View

Saes J, Schols S, van Heerde W, Nijziel M . Hemorrhagic disorders of fibrinolysis: a clinical review. J Thromb Haemost. 2018; . DOI: 10.1111/jth.14160. View

Greineder C, Howard M, Carnemolla R, Cines D, Muzykantov V . Advanced drug delivery systems for antithrombotic agents. Blood. 2013; 122(9):1565-75. PMC: 3757370. DOI: 10.1182/blood-2013-03-453498. View

Wahid L, Ortel T . Anticoagulant Therapy in Patients Hospitalized With COVID-19. JAMA Intern Med. 2021; 181(12):1621-1622. DOI: 10.1001/jamainternmed.2021.6212. View

Landowski L, Niego B, Sutherland B, Hagemeyer C, Howells D . Applications of Nanotechnology in the Diagnosis and Therapy of Stroke. Semin Thromb Hemost. 2019; 46(5):592-605. DOI: 10.1055/s-0039-3399568. View

Mihalko E, Sandry M, Mininni N, Nellenbach K, Deal H, Daniele M . Fibrin-modulating nanogels for treatment of disseminated intravascular coagulation. Blood Adv. 2021; 5(3):613-627. PMC: 7876887. DOI: 10.1182/bloodadvances.2020003046. View

Undas A, Ariens R . Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011; 31(12):e88-99. DOI: 10.1161/ATVBAHA.111.230631. View

10.

Flick M . Mechanism of ICH with tPA thrombolysis. Blood. 2021; 138(1):8-9. DOI: 10.1182/blood.2021011268. View

11.

Fay W, Garg N, Sunkar M . Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol. 2007; 27(6):1231-7. DOI: 10.1161/ATVBAHA.107.140046. View

12.

Huang G, Zhou Z, Srinivasan R, Penn M, Kottke-Marchant K, Marchant R . Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. Biomaterials. 2008; 29(11):1676-85. PMC: 2278119. DOI: 10.1016/j.biomaterials.2007.12.015. View

13.

Stewart D, Kong M, Novokhatny V, Jesmok G, Marder V . Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood. 2002; 101(8):3002-7. DOI: 10.1182/blood-2002-08-2546. View

14.

Huang Y, Gu B, Salles-Crawley I, Taylor K, Yu L, Ren J . Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy. Sci Adv. 2021; 7(23). PMC: 8172176. DOI: 10.1126/sciadv.abf9033. View

15.

Vo A, Swaroop A, Liu Y, Norris Z, Shavit J . Loss of fibrinogen in zebrafish results in symptoms consistent with human hypofibrinogenemia. PLoS One. 2013; 8(9):e74682. PMC: 3787019. DOI: 10.1371/journal.pone.0074682. View

16.

Jagadeeswaran P, Cooley B, Gross P, Mackman N . Animal Models of Thrombosis From Zebrafish to Nonhuman Primates: Use in the Elucidation of New Pathologic Pathways and the Development of Antithrombotic Drugs. Circ Res. 2016; 118(9):1363-79. DOI: 10.1161/CIRCRESAHA.115.306823. View

17.

Rost M, Grzegorski S, Shavit J . Quantitative methods for studying hemostasis in zebrafish larvae. Methods Cell Biol. 2016; 134:377-89. PMC: 5023325. DOI: 10.1016/bs.mcb.2016.01.003. View

18.

Gasecka A, Borovac J, Guerreiro R, Giustozzi M, Parker W, Caldeira D . Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment. Cardiovasc Drugs Ther. 2020; 35(2):215-229. PMC: 7569200. DOI: 10.1007/s10557-020-07084-9. View

19.

Plow E, DSouza S, Ginsberg M . Ligand binding to GPIIb-IIIa: a status report. Semin Thromb Hemost. 1992; 18(3):324-32. DOI: 10.1055/s-2007-1002571. View

20.

Sun M, Sen Gupta A . Vascular Nanomedicine: Current Status, Opportunities, and Challenges. Semin Thromb Hemost. 2019; 46(5):524-544. PMC: 10071587. DOI: 10.1055/s-0039-1692395. View